Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
38.35-0.22 (-0.57%)
At close: 4:02 PM EDT
People also watch:
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open38.30
Prev Close38.57
Bid37.89 x 5500
Ask37.97 x 5600
Day's Range38.28 - 38.54
52wk Range37.41 - 51.88
1y Target EstN/A
Market Cap98.71B
P/E Ratio (ttm)21.39
Beta0.90
Volume1,049,503
Avg Vol (3m)2,454,938
Dividend & Yield1.66 (4.34%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Sanofi may win U.S. approval of $3 billion eczema drug by March

    Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29. Dupilumab, an injectable antibody drug, is seen by investors as perhaps Sanofi's most promising pipeline medicine, since it has produced promising clinical results and could be first systemic therapy for severe AD.

  • PR Newswire5 hours ago

    Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

    TARRYTOWN, N.Y. and PARIS, Sept. 26, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease. To access this call, dial (888) 771-4371 (U.S.), 0805 102 604 (France), or 0808 238 9578 (UK). The conference call will include a presentation followed by a Q&A session.

  • Reuters4 days ago

    Hard to swallow: emerging markets get tougher for drugmakers

    Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.